Health and Human Services Secretary Robert F. Kennedy Jr. has directed the Food and Drug Administration to move forward with a proposal aimed at closing a longstanding regulatory gap that allows novel food ingredients to enter the U.S. supply without direct FDA review. The initiative, announced Monday, takes specific aim at the "generally recognized as safe," or GRAS, designation process.
The current system permits manufacturers to self-affirm the safety of new ingredients, often submitting notifications to the agency but utilizing food scientists employed by or paid by the very corporations seeking approval. Administration officials argue this framework places the interests of globalist food conglomerates and corporate lobbying ahead of American public health. The domestic economic impact is undeniable, with diet-related chronic diseases like obesity and diabetes cited as a primary driver of workforce attrition and soaring national healthcare expenditures that fall on taxpayers.
"For too long, ingredient manufacturers and sponsors have exploited a loophole that has allowed new ingredients and chemicals, often with unknown safety data, to be introduced into the U.S. food supply without notification to the FDA or the public," HHS Secretary Kennedy stated. "Eliminating this loophole will provide transparency to consumers, help get our nation's food supply back on track and ensure that ingredients being introduced into foods are safe before they are marketed to the American people."
The proposed rule would mandate that industry notify the FDA of any self-determined GRAS conclusion and submit underlying safety data for public review, effectively ending the practice of private safety determinations. While the agency stressed that no immediate changes to store shelves are expected, the proposal represents a direct challenge to the food processing industry’s autonomy over its supply chain. HHS plans to issue a proposed rule to revise the GRAS framework, a process likely to face significant pushback from food manufacturing giants who have long benefited from a streamlined, low-cost pathway to market for novel additives.
The timing of the announcement comes as the administration seeks to demonstrate tangible action on public health pledges without committing general fund dollars to expansive new government programs. By forcing industry to bear the cost of proving safety, the proposal functions as a form of economic nationalism in the regulatory space, shifting the burden back onto profitable corporations rather than American families and workers who bear the medical costs of chronic disease.